HC Wainwright & Co. Reiterates Buy on Nuvectis Pharma, Maintains $21 Price Target

Benzinga · 09/15/2023 10:10
HC Wainwright & Co. analyst Joseph Pantginis reiterates Nuvectis Pharma (NASDAQ:NVCT) with a Buy and maintains $21 price target.